| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net income | - | -1 | 14 | 24 | -4 | 32 | 8 | 6 | 24 | 5 | 26 | 13 |
|---|
| Provision for credit losses | - | - | - | - | 11 | - | - | - | - | - | - | 3 |
|---|
| Amortization of debt issuance costs | - | - | 0 | 0 | 0 | - | 0 | - | 0 | 0 | 0 | 0 |
|---|
| Deferred income taxes | - | - | - | - | 3 | -22 | 16 | 0 | -7 | -2 | 7 | -4 |
|---|
| Change in fair value of warrants | - | - | - | -0 | 3 | -1 | 1 | -0 | -0 | 1 | -0 | -0 |
|---|
| Unrealized net (loss) gain on equity securities | - | - | - | - | - | - | - | -1 | 2 | -1 | 2 | -1 |
|---|
| Foreign currency transaction loss | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Realized loss on sale of investments | - | - | - | - | - | - | 0 | -0 | 0 | 0 | -0 | -0 |
|---|
| Change in fair value of acquisition-related contingent consideration | - | - | - | - | - | - | - | - | - | 4 | -0 | 5 |
|---|
| Loan discount and fee accretion | - | - | 1 | 0 | 2 | 3 | 2 | -0 | 0 | 2 | 1 | 2 |
|---|
| Interest paid-in-kind | - | - | -0 | -4 | -1 | - | 2 | 0 | 1 | 2 | 1 | 6 |
|---|
| Stock-based compensation | 0 | 586,000 | 254,000 | 1 | 1 | 0 | -1 | 0 | 1 | 1 | 1 | 1 |
|---|
| Depreciation and amortization | 0 | 0 | 0 | - | - | - | - | - | - | 19 | 4 | 3 |
|---|
| Interest and accounts receivable | - | - | - | - | - | - | - | - | -0 | 1 | 0 | -1 |
|---|
| Derivative assets and liabilities, net | - | - | - | - | - | - | - | - | - | - | - | -1 |
|---|
| Other assets | - | - | - | - | 1 | 0 | 0 | -0 | 0 | 1 | 2 | 0 |
|---|
| Accounts payable and other liabilities | -0 | -0 | 0 | 0 | -0 | -0 | 1 | -1 | 2 | 2 | 2 | -2 |
|---|
| Net cash provided by operating activities | -1 | -1 | 1 | 5 | 11 | 10 | 19 | 20 | 19 | 19 | 34 | 8 |
|---|
| Proceeds from sale of marketable investments | - | - | - | - | - | - | - | - | - | - | - | 4 |
|---|
| Cash received from settlement of warrants and equity securities | - | - | - | - | - | - | - | - | - | 0 | 2 | - |
|---|
| Investment in finance receivables | - | 7 | 30 | -10 | - | - | 37 | 90 | 51 | 43 | 42 | 93 |
|---|
| Repayment of finance receivables | - | - | - | - | - | - | 7 | 62 | 44 | 12 | 67 | 46 |
|---|
| Corporate debt securities principal payments | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Purchases of property and equipment | - | 0 | 0 | 0 | 0 | - | - | - | - | 4 | 1 | 0 |
|---|
| Net cash (used in) provided by investing activities | 0 | -20 | -20 | -56 | -19 | -21 | -12 | -28 | -27 | -35 | 26 | -44 |
|---|
| Net settlement for employee taxes on restricted stock and options | - | - | - | - | - | - | - | - | - | - | -0 | -0 |
|---|
| Repurchases of common stock, including fees and expenses | - | - | - | - | - | - | - | 1 | 1 | 2 | - | 1 |
|---|
| Net proceeds from (payments on) credit facility | - | - | - | - | - | - | - | - | - | 12 | -12 | 2 |
|---|
| Payment of acquisition-related contingent consideration | - | - | - | - | - | - | - | - | - | 2 | 8 | 3 |
|---|
| Net cash used in financing activities | - | 7 | 2 | 102 | -4 | -4 | -9 | -2 | -1 | 8 | -20 | -1 |
|---|
| Net (decrease) increase in cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | 40 | -37 |
|---|
| Warrants received in connection with finance receivables | - | - | - | - | - | - | 1 | 1 | 0 | 0 | 0 | 1 |
|---|
| Cash paid for interest | - | - | - | 0 | - | - | - | - | - | - | - | 0 |
|---|
| Fair value of common stock received in connection with payoff of term loan | - | - | - | - | - | - | - | - | - | - | 1 | - |
|---|
| Fair value of common stock received upon exercise of warrant | - | - | - | - | - | - | - | - | - | - | - | 4 |
|---|